Zimbabwe

A snapshot of PrEP scale-up, registration and resources for Zimbabwe.

8,700-9,200

Estimated Number of Current PrEP Users

Aggregates numbers reported from demonstration projects, PEPFAR dashboard and program/country reports where available. This is presented as a range due to difficulty in tracking precise numbers and possible double reporting.

10,574

National Health System Targets

National targets put forward by governments may be aspirational and/or indicative of estimated need; or they may be low or nonexistent if PrEP is solely available via demonstration projects. In some instances, national targets may not include targets from all planned and ongoing PrEP demonstration projects. For these reasons, a calculation of current PrEP users as a percentage of this target will not necessarily reflect accurate progress in PrEP initiations at the country level.

2,769

PEPFAR PrEP Target in COP 2018

Targets are set by PEPFAR country teams on an annual basis. Targets do not indicate funding is available for PrEP.

Data Updated: December 31, 2018

Drug Registration Status

Gilead's Truvada (TDF/FTC) registration

Approved

Generic versions of TDF/FTC for prevention

Approved

Types of Delivery Projects

Behavioral and social science projects

Clinical trials

Implementation projects — funded/implementer involvement and investment in some or all steps related to comprehensive introduction that may or may not use government

Large-scale implementation initiative — funded/implementer involvement and investment in some or all steps related to comprehensive introduction that may or may not use government clinics as the primary service delivery point – e.g., Kenya’s Jilinde program.

Funding

Selected Technical & Strategic Assistance

Eligibility Criteria

Oral PrEP will be made available to all individuals who are HIV uninfected and are at substantial risk of HIV infection after individual risk assessment. The following are indications for PrEP by history over the past 6 months:

HIV negative and sexual partner with HIV who has not been on effective therapy for the preceding 6 months OR

HIV negative and sexually active in a high HIV prevalence population AND any of the following:

Vaginal or anal intercourse without condoms with more than one partner, OR

A sexual partner with one or more HIV risk factors, OR

A history of an STI by lab testing or self-report or syndromic STI treatment, OR

Any use of post-exposure prophylaxis (PEP), OR

Requesting PrEP

However, individuals belonging to certain population groups may be at higher risk of HIV infection than others and should be offered PrEP. These may include:

Female and male sex workers;

Sero-discordant couples (the HIV sero-negative partner)

Adolescent girls and young women;

Pregnant women in relationships with men of unknown status

High-risk men (MSMs, prisoners, long distance truck drivers) and

Transgender people.

Individual risk assessment will be made based on various behavioral factors and other factors to assess vulnerability.

Resources for Zimbabwe

The Dapivirine Ring Introduction Matrix – The ring introduction matrix is an early-stage implementation tool intended to help policymakers and implementers consider the introduction of the dapivirine ring alongside oral PrEP.

Sample PrEP jingles, written by local Zimbabwe artists and developed with the support of OPTIONS for use in the Zimbabwe oral PrEP launch on June 15, 2018. This jingle was developed by a young transgender woman in Zimbabwe for the purpose of sharing the benefits of PrEP with her peers. Similarly, this adaptation of the popular song ‘Tipei maoko’ by well-known local artist Tocky Vibes includes PrEP messaging throughout.

The IMPAACT Network is planning a study in Zimbabwe examining PrEP adherence among HIV-uninfected pregnant adolescents and young women, comparing pregnancy outcomes among women who take PrEP and women who decline PrEP during the antenatal period.

PrEP Watch was created and is maintained by AVAC, a non-profit organization based in New York that uses education, policy analysis, advocacy and a network of global collaborations to accelerate the ethical development and global delivery of new and emerging HIV prevention options as part of a comprehensive response to the HIV/AIDS pandemic. AVAC receives no money from pharmaceutical companies, including Gilead Sciences. If you have a comment or suggestion regarding the content of this site, click here to contact us. Read our privacy policy.